Robert A. Olson

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Journal: Journal of telemedicine and telecare

Published: August 10, 2026

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Journal: Journal of telemedicine and telecare

Published: August 10, 2026

Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).

Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE).

Journal: The Prostate

Published: May 18, 2026

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 21, 2026

In Regard to Golden.

In Regard to Golden.

Journal: International journal of radiation oncology, biology, physics

Published: February 10, 2026

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: February 03, 2026

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Journal: International journal of radiation oncology, biology, physics

Published: October 24, 2025

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis.

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: September 11, 2025

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Journal: The Lancet. Oncology

Published: August 11, 2025

Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).

Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).

Journal: BMC cancer

Published: July 09, 2025

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Multinational validation of distant metastasis velocity as a post-progression prognostic score in patients with oligometastatic cancer treated with metastasis-directed stereotactic body radiotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2025

Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.

Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 10, 2025

Showing 1-12 of 139

Last Updated: 09/26/2026